Insilico exploration C. koseri ATP synthase inhibitors by pharmacophore-based virtual screening, molecular docking and MD simulation.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Molecular Docking Simulation* ; Molecular Dynamics Simulation* ; Pharmacophore*; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/chemistry ; Drug Design ; Drug Evaluation, Preclinical ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacology ; Ligands

Citrobacter koseri is a gram-negative rod that causes infections in people who have significant comorbidities and are immunocompromised. Antibiotic-resistant strains are becoming more common, which complicates infection treatment and highlights the need for innovative, effective drugs to fight these resistant strains. The enzyme complex ATP synthase participates in the adenosine triphosphate (ATP) synthesis, the fundamental energy currency of cells. This study used Computer-Aided Drug Design approaches to identify potential inhibitors of C. koseri ATP synthase. SWISS-MODEL was used to predict the 3D structure of C. koseri ATP synthase. A ligand-based pharmacophore model was developed using chemical features of ampicillin. Following ligand-based virtual screening across nine databases, the 2043 screened hits were docked to the ATP synthase active site using the standard precision mode of the glide tool. Based on their binding affinities, the top ten compounds were selected for additional investigation. The binding affinities of the chosen compounds ranged from -10.021 to -8.452 kcal/mol. The top four compounds (PubChem-25230613, PubChem-74936833, CHEMBL263035, PubChem-44208924) with the best ADMET characteristics and binding modes were chosen. Thus, the feasible binding mechanisms of the selected compounds were subjected to stability analysis using the MD Simulation study, which revealed the compounds' stability as potent inhibitors within the protein binding pocket. This computational approach provides important insights into the rational design of novel therapeutics and emphasizes the importance of targeting essential metabolic pathways when combating antibiotic-resistant pathogens. Future experimental validation and optimization of the identified inhibitors is required to determine their efficacy and safety profiles for clinical use.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Alanzi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Clin Med Insights Case Rep. 2016 Oct 06;9:87-89. (PMID: 27746678)
Int J Mol Sci. 2019 Sep 15;20(18):. (PMID: 31540192)
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241239544. (PMID: 38577758)
Science. 1992 Apr 10;256(5054):184-5. (PMID: 1566067)
J Med Chem. 2004 Mar 25;47(7):1739-49. (PMID: 15027865)
Eur J Med Chem. 2021 Nov 15;224:113705. (PMID: 34303871)
J Comput Chem. 2011 Oct;32(13):2800-9. (PMID: 21717478)
Int J Biochem Cell Biol. 2013 Jan;45(1):99-105. (PMID: 22664329)
Nucleic Acids Res. 2018 Jul 2;46(W1):W363-W367. (PMID: 29860391)
J Biomol Struct Dyn. 2018 Nov;36(15):3993-4009. (PMID: 29132266)
J Biomol Struct Dyn. 2023;41(23):14325-14338. (PMID: 36946192)
Int J Mol Sci. 2011;12(8):5304-18. (PMID: 21954360)
J Biomol Struct Dyn. 2022 Apr;40(6):2663-2673. (PMID: 33140698)
Infect Immun. 2003 Oct;71(10):5871-80. (PMID: 14500508)
Curr Top Med Chem. 2018;18(20):1755-1768. (PMID: 30360721)
Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5. (PMID: 1673839)
Front Microbiol. 2019 Dec 06;10:2774. (PMID: 31866966)
Protein Sci. 2021 Jan;30(1):20-30. (PMID: 32734663)
Bioinform Biol Insights. 2019 Jul 31;13:1177932219865533. (PMID: 31391779)
BMJ Case Rep. 2012 Jan 23;2012:. (PMID: 22665908)
Antivir Ther. 2016;21(7):595-603. (PMID: 27035622)
Curr Comput Aided Drug Des. 2010 Mar;6(1):37-49. (PMID: 20370694)
Mol Inform. 2020 Nov;39(11):e2000059. (PMID: 32578959)
J Mol Biol. 2005 Oct 14;353(1):38-52. (PMID: 16169013)
J Chem Inf Model. 2012 Apr 23;52(4):963-74. (PMID: 22486340)
BMC Neurol. 2009 Jun 12;9 Suppl 1:S1. (PMID: 19534730)
Mol Inform. 2011 May 16;30(5):398-404. (PMID: 27467085)
Clin Infect Dis. 1996 Sep;23(3):543-9. (PMID: 8879778)
Molecules. 2020 Oct 15;25(20):. (PMID: 33076254)
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. (PMID: 11259830)
PLoS One. 2015 Mar 27;10(3):e0119264. (PMID: 25816325)
Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444. (PMID: 34791371)
Biomol Concepts. 2019 Mar 7;10(1):1-10. (PMID: 30888962)
Pharmaceuticals (Basel). 2022 May 23;15(5):. (PMID: 35631472)
Nature. 2021 Aug;596(7873):583-589. (PMID: 34265844)
J Chem Theory Comput. 2017 Apr 11;13(4):1518-1524. (PMID: 28267328)
Rev Infect Dis. 1980 Sep-Oct;2(5):746-60. (PMID: 6763304)
Expert Rev Anti Infect Ther. 2014 Sep;12(9):1137-42. (PMID: 25088467)
J Comput Aided Mol Des. 2013 Mar;27(3):235-46. (PMID: 23579613)
J Chem Theory Comput. 2012 Aug 14;8(8):2553-8. (PMID: 26592101)
Annu Rev Biochem. 2015;84:631-57. (PMID: 25839341)
Biomolecules. 2022 Dec 23;13(1):. (PMID: 36671415)
Molecules. 2018 Oct 04;23(10):. (PMID: 30287782)
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. (PMID: 29788355)
Curr Top Med Chem. 2019;19(19):1751-1767. (PMID: 31418662)
Nucleic Acids Res. 2015 Jan;43(Database issue):D204-12. (PMID: 25348405)
Nucleic Acids Res. 2016 Jul 8;44(W1):W442-8. (PMID: 27095195)
Antibiotics (Basel). 2021 Jul 21;10(8):. (PMID: 34438937)
Arab J Chem. 2022 Dec;15(12):104334. (PMID: 36246784)
Nat Chem. 2012 Jan 24;4(2):90-8. (PMID: 22270643)
J Chem Inf Model. 2012 Nov 26;52(11):3099-105. (PMID: 23092397)
Brief Bioinform. 2020 Sep 25;21(5):1663-1675. (PMID: 31711157)
Intern Med. 2019 Mar 15;58(6):813-816. (PMID: 30449805)
J Comput Chem. 2013 Sep 30;34(25):2135-45. (PMID: 23832629)
Front Cell Infect Microbiol. 2021 Aug 27;11:737636. (PMID: 34513738)
Chem Biol Interact. 2008 Jan 30;171(2):165-76. (PMID: 17229415)
SAGE Open Med Case Rep. 2022 Nov 1;10:2050313X221135347. (PMID: 36337163)

0 (Anti-Bacterial Agents)
0 (Enzyme Inhibitors)
0 (Ligands)

Date Created: 20240822 Date Completed: 20240822 Latest Revision: 20240828

20240828

PMC11341028

10.1371/journal.pone.0308251

39173004